Exhibit
99.2
FOR
IMMEDIATE RELEASE
Oragenics
Announces Plans for 2006 and Formation of an International Advisory
Committee
ALACHUA,
FL (February 27, 2006): Oragenics,
Inc. (AMEX:ONI) announced today that its President and CEO, Dr. Robert
Zahradnik, has outlined plans for the company for the remainder of 2006 in
a
Letter to Shareholders. This letter can be accessed in its entirety at the
company’s web site at www.oragenics.com.
The
company plans to pursue a global strategy in 2006 for conducting clinical trials
for SMaRT™ replacement therapy. Significant progress has been made in
preclinical trials with its novel antibiotic, MU1140, and this product could
be
in clinical trials by late 2006. The company also plans to begin a human trial
for its Probiora-3™ probiotic product by the summer 2006. As stated by Dr.
Zahradnik, “Oragenics will continue to build momentum toward licensing and
commercialization of its lead products, SMaRT™ replacement therapy, MU1140™
antibiotic, and Probiora-3™ probiotic by focusing its resources on these
development programs and the initiation of clinical trials.”
In
other
news, the company announced that Dr. Raman Bedi, senior consultant and Chair,
has enlisted three of the world’s leading experts in oral health as members of
its International Advisory Committee. The members include Dr. Brian Mouatt,
past
Chief Dental Officer of England and currently Chair of the FDI World Dental
Development Committee; Dr. Ayyaz Khan, Head of the Department of Oral Health
Sciences at the Shaikh Zayed Medical Institute in Lahore, Pakistan; and Dr.
Hari
Parkash, Director ITS Center Dental Studies and Research, Ghaziabad, India.
Professor Bedi said, “I am delighted that these three world class researchers
are joining the International Advisory Committee. They each bring a wealth
of
experience and understanding of global dental policy which will help us shape
Oragenics’ strategic plans.”
For
more
information about Oragenics, please consult the company’s web site at
www.oragenics.com.
Safe
Harbor Statement: Under the Private Securities Litigation Reform Act of 1995:
This release includes forward-looking statements that reflect Oragenics’ current
views with respect to future events and financial performance. These
forward-looking statements are based on management’s beliefs and assumptions and
information currently available. The words “believe,” “expect,” “anticipate,”
“intend,” “estimate,” “project” and similar expressions that do not relate
solely to historical matters identify forward-looking statements. Investors
should be cautious in relying on forward-looking statements because they are
subject to a variety of risks, uncertainties, and other factors that could
cause
actual results to differ materially from those expressed in any such
forward-looking statements. These factors include, but are not limited to (1)
the ability to successfully complete development and commercialization of
Oragenics’ Replacement Therapy for prevention of tooth decay, novel antibiotic,
and probiotic for oral health; (2) the ability to obtain substantial additional
funding; (3) the ability to develop and commercialize products before
competitors; (4) the ability to develop and commercialize products with the
in-licensed technology; and (5) other factors detailed from time to time in
filings with the Securities and Exchange Commission. We expressly disclaim
any
responsibility to update forward-looking statements.
Contact:
Oragenics,
Inc.
Paul
A.
Hassie, 386-418-4018 X232
www.oragenics.com